Evidence map›Paper›PMID 41993168›Full record

ArticleFrontiers in immunology2026

A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer.

Yoshihiko Goto, Garry Dolton, Hannah Thomas, Théo Morin, Yuka Tajima, Kosuke Imamura, Shinya Sakata, Kentaro Oka, Atsushi Hayashi, Motomichi Takahashi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yoshihiko Goto *Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Garry Dolton *Division of Infection and immunity Cardiff University School of Medicine, Cardiff, United Kingdom.
Hannah ThomasDivision of Infection and immunity Cardiff University School of Medicine, Cardiff, United Kingdom.
Théo MorinDivision of Infection and immunity Cardiff University School of Medicine, Cardiff, United Kingdom.
Yuka TajimaDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Kosuke ImamuraDepartment of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Shinya SakataDepartment of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Kentaro OkaR&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan.
Atsushi HayashiR&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan.
Motomichi TakahashiR&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan.
Takamasa UenoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Takuro SakagamiDepartment of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Yusuke TomitaDepartment of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Andrew K Sewell *Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Chihiro Motozono *Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The link between the intestinal microflora and cancer outcomes has been recognized for over a decade. Several recent studies have demonstrated that the gut microbiome is associated with the efficiency of T-cell checkpoint blockade therapy for cancer, raising interest in strategies to harness this effect via consumption of live microorganisms (probiotics). The probiotic

Indexed as

Carcinoma, Non-Small-Cell LungClostridium butyricumIntraepithelial LymphocytesLung NeoplasmsProbioticsReceptors, Antigen, T-Cell, gamma-deltaAgedAntigens, CDAntigens, Differentiation, T-LymphocyteCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsLymphocyte ActivationMaleMiddle AgedAntigens, CDAntigens, Differentiation, T-LymphocyteImmune Checkpoint InhibitorsReceptors, Antigen, T-Cell, gamma-deltabutyrophilin 3AClostridium butyricum (CBM588)gamma delta (γδ) T-cellsimmune checkpoint inhibitors (ICIs)microbiomenon-small cell lung cancer (NSCLC)probioticVγ9Vδ2 T-cells

Identifiers

PMID41993168
PMCPMC13079699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.